# LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

> **NCT02205762** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **North American Consortium for Histiocytosis** · enrollment: 1400 (actual)

## Conditions studied

- Langerhans Cell Histiocytosis

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Vinblastine
- **DRUG:** mercaptopurine
- **DRUG:** INDOMETHACIN
- **DRUG:** Methotrexate
- **DRUG:** Cytosine Arabinoside
- **DRUG:** 2-chlorodeoxyadenosine
- **PROCEDURE:** hematopoietic stem cell transplantation (RIC-HSCT)
- **BIOLOGICAL:** Intravenous immunoglobulin

## Key facts

- **NCT ID:** NCT02205762
- **Lead sponsor:** North American Consortium for Histiocytosis
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-02
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 1400 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02205762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02205762, "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02205762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*